Notice of Annual General Meeting in Intervacc AB (publ)
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”)…
Echtzeit-Aktienkurs INTERVACC AB
Bid:
Ask:
Nachrichten zur INTERVACC AB Aktie
Intervacc publishes the 2024 Annual Report
Intervacc AB (publ) announces that the companys 2024 Annual Report has been published today. The annual report (in Swedish) is…
Intervaccs variation application approved by VMD
Intervacc AB (publ) today announces that the variation application previously submitted to the U.K’s Veterinary Medicines Directorate, (VMD), has now…
Intervacc announces changes in the Nomination Committee
Stockholm, March 17, 2025 – The composition of the Nomination Committee in Intervacc AB (publ) (“Intervacc”) has changed due to…
Intervacc announces the outcome of the rights issue
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF…
Intervaccs variation application approved by European Medicines Agency
Stockholm, February 13, 2025 – Intervacc AB (publ) today announces that the variation application previously submitted to the European Medicines…
Intervacc AB (publ) publishes supplement to the prospectus regarding the rights issue
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF…
Intervacc AB (publ) publishes prospectus regarding the rights issue
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF…
Notice of Extraordinary General Meeting in Intervacc AB (publ)
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Extraordinary General Meeting (“EGM”)…
The Board of Directors of Intervacc resolves on a rights issue of approximately SEK 225 million
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF…
Strangvac is back in stock on all launched markets
Stockholm, December 6, 2024 – Intervacc AB (publ) announces that Strangvac, a vaccine against equine strangles, is now back in…
Invitation to conference call and audiocast in connection with the interim report
Stockholm, November 11, 2024 – Intervacc AB (publ) will publish its interim report for the period January to September 2024…
Out-of-stock situation regarding Strangvac in Sweden resolved
Stockholm, October 21, 2024 – Intervacc AB (publ) announces that the shortage situation for the equine strangles vaccine Strangvac in…
Intervacc identifies a potential short out-of-stock situation regarding Strangvac
Stockholm, September 20, 2024 - Intervacc AB (publ) predicts that the vaccine Strangvac, which is approved for sale in Europe…
Extended Patent Protection for Strangvac approved in the United Kingdom
Stockholm, September 20, 2024 – Intervacc AB (publ) announces that the application for supplementary protection for Strangvac, an innovative vaccine…
Intervacc and the Karolinska Institutet extends contract for the development of innovative animal health vaccines
Stockholm, August 15, 2024 –Intervacc AB (publ) and the Karolinska Institute, KI, announce that they have extended their collaboration to…
Intervacc has presented new findings at the ACVIM Forum in the United States
Stockholm, June 13th, 2024 – Intervacc AB (publ) has presented new reports highlighting the importance of vaccination to disease control…
Notice of Annual General Meeting in Intervacc AB (publ)
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”)…
Intervacc publishes the 2023 Annual Report
Stockholm, April 10, 2024 - Intervacc AB (publ) announces that the companys 2023 Annual Report has been published today. The…
Intervacc announces changes in the Nomination Committee
Stockholm, March 4, 2024 – The composition of the Nomination Committee in Intervacc AB (publ) (“Intervacc”) was announced in a…
Jonas Sohlman appointed as new CEO for Intervacc
Stockholm, February 28, 2024 - The Board of Directors for Intervacc AB (publ) announces that acting CEO Jonas Sohlman has…